Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Quantitative analysis of somatically acquired and constitutive uniparental disomy in gastrointestinal cancers

  • Torabi Asensio, Keyvan|||0000-0002-9067-0061
  • Erola, Pau
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Ferrer Menduiña, Queralt|||0000-0003-3177-4618
  • Castells, Antoni|||0000-0001-8431-2033
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Milà, Montserrat
  • Lozano, Juan José
  • Miró Ametller, Rosa|||0000-0003-2508-5074
  • Ried, Thomas|||0000-0002-0767-6009
  • Ponsa Arjona, Immaculada|||0000-0003-3436-1907
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatically acquired uniparental disomies (aUPDs) are frequent events in solid tumors and have been associated with cancer-related genes. Studies assessing their functional consequences across several cancer types are therefore necessary. Here, we aimed at integrating aUPD profiles with the mutational status of cancer-related genes in a tumor-type specific manner. Using TCGA datasets for 1,032 gastrointestinal cancers, including colon (COAD), rectum (READ), stomach (STAD), esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), we show a non-random distribution of aUPD, suggesting the existence of a cancer-specific landscape of aUPD events. Our analysis indicates that aUPD acts as a "second hit" in Knudson's model in order to achieve biallelic inactivation of tumor suppressor genes. In particular, APC , ARID1A and NOTCH1 were recurrently inactivated by the presence of homozygous mutation as a consequence of aUPD in COAD and READ, STAD and ESCC, respectively. Furthermore, while TP53 showed inactivation caused by aUPD at chromosome arm 17p across all tumor types, copy number losses at this genomic position were also frequent. By experimental and computationally inferring genome ploidy, we demonstrate that an increased number of aUPD events, both affecting the whole chromosome or segments of it, were present in highly aneuploid genomes compared to near-diploid tumors. Finally, the presence of mosaic UPD was detected at a higher frequency in DNA extracted from peripheral blood lymphocytes of patients with colorectal cancer compared to healthy individuals. In summary, our study defines specific profiles of aUPD in gastrointestinal cancers and provides unequivocal evidence of their relevance in cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications

  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Vila-Casadesús, Maria|||0000-0001-6597-7953
  • Hernández-Illán, Eva
  • Esteban-Fabró, Roger
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Llovet, Josep Maria
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here, we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at . In most cases, human cells contain two copies of each of their genes, yet sometimes this can change, an effect called copy number alteration (CNA). Cancer is a genetic disease and thus, studying the DNA from tumor samples is crucial to improving diagnosis and choosing the right treatment. Most tumors contain cells with CNAs; however, the impact of CNAs in cancer progression is poorly understood. CNAs can be studied by examining the genome of tumor cells and finding which regions display an unusual number of copies. It may also be possible to gather information about different cancer types by analyzing the CNAs in a tumor, but this approach requires the analysis of large amounts of data. To aid the analysis of CNAs in cancer cells, Franch-Expósito, Bassaganyas et al. have created an online tool called CNApp, which is able to identify and count CNAs in genomic data and link them to features associated with different cancers. The hope is that a better understanding of the effect of CNAs in cancer could help better diagnose cancers, and improve outcomes for patients. Potentially, this could also predict what type of treatment would work better for a specific tumor. Besides, by using a machine-learning approach, the tool can also make predictions about specific cancer subtypes in order to facilitate clinical decisions. Franch-Expósito, Bassaganyas et al. tested CNApp using previously existing cancer data from 33 different cancer types to show how CNApp can help the interpretation of CNAs in cancer. Moreover, CNApp can also use CNAs to identify different types of bowel (colorectal) cancer in a way that could help doctors to make decisions about treatment. Together these findings show that CNApp provides an adaptable and accessible research tool for the study of cancer genomics, which could provide opportunities to inform medical procedures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer

  • Fernández-Rozadilla, Ceres|||0000-0001-7330-4804
  • Álvarez-Barona, Miriam|||0000-0002-3843-7481
  • Quintana, Isabel
  • López-Novo, Jorge Amigo
  • Amigo, Jorge|||0000-0002-1362-2605
  • Cameselle-Teijeiro, José Manuel|||0000-0002-5516-8914
  • Roman, Eva|||0000-0001-9084-8555
  • Gonzalez, Dolors
  • Llor, Xavier|||0000-0002-6259-185X
  • Bujanda, Luis|||0000-0002-4353-9968
  • Bessa Caserras, Xavier|||0000-0003-4680-1228
  • Jover, Rodrigo
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Castells, Antoni|||0000-0001-8431-2033
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Capella, Gabriel|||0000-0002-4669-7320
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Valle, Laura|||0000-0003-0371-0844
  • Ruiz-Ponte, Clara|||0000-0002-2200-0162
Colorectal cancer (CRC) is a complex disease that can be caused by a spectrum of genetic variants ranging from low to high penetrance changes, that interact with the environment to determine which individuals will develop the disease. In this study, we sequenced 20 early-onset CRC patients to discover novel genetic variants that could be linked to the prompt disease development. Eight genes, CHAD, CHD1L, ERCC6, IGTB7, PTPN13, SPATA20, TDG and TGS1, were selected and re-sequenced in a further 304 early onset CRC patients to search for rare, high-impact variants. Although we found a recurring truncating variant in the TDG gene shared by two independent patients, the results obtained did not help consolidate any of the candidates as promising CRC predisposing genes. However, we found that potential risk alleles in our extended list of candidate variants have a tendency to appear at higher numbers in younger cases. This supports the idea that CRC onset may be oligogenic in nature and may show molecular heterogeneity. Further, larger and robust studies are thus needed to unravel the genetics behind early-onset CRC development, coupled with novel functional analyses and omic approaches that may offer complementary insight.